Caplin Point has received approval from Brazil's National Health Surveillance Agency ANVISA (Agência Nacional de Vigilância Sanitária) for its sterile injectable manufacturing site at Chennai. With this approval the company gains access to register and market its products in the Brazilian pharmaceutical market.
Caplin's facility was also recently approved by EU-GMP in July 2015. Caplin manufactures liquid injectables in vials, ampoules, lyophilized vials and ophthalmic dosages at this site.
Caplin Point Laboratories Limited is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa.
Caplin Point caters to a complete range of finished dosage forms. The company currently holds over 1600 product licenses across Latin America and Africa with another 400 in the pipeline. It is believed that the company will also be filing its first ANDAs by early 2016.